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Antiplatelet therapy and development of hypertension induced by
recombinant human erythropoietin in uremic patients. The pathogenesis
of hypertension induced by recombinant human erythropoietin
(rHuEPO) remains a subject of intense interest. The observation that
patients treated with antiplatelet drugs never developed hypertension
following rHuEPO therapy prompted us to study retrospectively the
incidence and risk factors associated with the development of hyper-
tension in 91 patients on renal replacement therapy who had com-
menced rHuEPO therapy in the last three years. Logistic regression
analysis was used to determine the risk factors associated with the
development or aggravation of hypertension during the first six months
on rHuEPO therapy. The predictors were: age, gender, number of
months on dialysis, antecedent of hypertension, use of antiplatelet
drugs, and those parameters related with dose, route and magnitude of
the hematological response to rHuEPO. Of the 91 patients studied, 34
developed hypertension (37%). Of the 34 patients who were on anti-
platelet treatment, 2 (5.8%) developed hypertension, whereas among 57
who did not receive antiplatelet drugs, 32 (56%) developed it. By
multiple logistic regression analysis, the best predictive variables over
the development of hypertension were: age (odds ratio: 0.959, P =
0.02), antecedent of hypertension (odds ratio: 6.52, P = 0.002), and use
of antiplatelet therapy (odds ratio: 0.030, P < 0.0001). The rest of the
studied variables failed to explain the development of hypertension.
Antiplatelet therapy may prevent the development of hypertension in
patients treated with rHuEPO. Since the antiplatelet drugs used in this
study did not have a significant hemodynamic effect, we infer that
changes in platelet aggregability induced by rHuEPO may be involved
in the pathogenesis of hypertension induced by this hormone.
Recombinant human erythropoietin (rHuEPO) has been
shown to be an excellent drug to reverse anemia in uremic
patients with few adverse effects. Among these adverse effects,
the development or aggravation of arterial hypertension is one
of the most common [1—5], becoming in some cases severe
enough to increase the morbidity of these patients [2, 3, 6, 7].
The mechanism(s) by which erythropoietin increases arterial
blood pressure in uremic patients remains a subject of intense
interest.
To date many studies have failed to show a clear association
between the increment in blood pressure induced by rHuEPO
therapy and several mechanisms which are commonly involved
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in the pathogenesis of arterial hypertension [8—14]. The failure
of adequate cardiovascular autoregulation and the loss of hy-
poxic vasodilation have been considered plausible causes of
this phenomenon [8, 15]. One of the most striking features of
rHuEPO-induced hypertension is that this is only seen when the
hormone is administered to uremic patients but not in those
non-uremic with other types of anemia [16—18]. Therefore, the
pathogenesis of this increment in blood pressure might be in
relationship with any selective change provoked by this hor-
mone in the uremic organism.
The incidence of blood pressure increase in large series of
patients treated with rHuEPO ranges between 20% and 35%
[1—5]. This increment in blood pressure can be seen shortly after
the commencement of rHuEPO—from 2 to 16 weeks in the
majority of cases [3, 19, 20]—mitigating its severity after this
time [3, 21]. An unequivocal factor which places these patients
at risk to develop hypertension following rHuEPO therapy has
not yet been identified. A history of previous hypertension [2,
3], the rapid increment in hematocrit [22], the dosage and route
of rHuEPO administration [23] or the most severe anemia
before rHuEPO therapy [7, 19, 24], have been suggested as
possible risk factors, although not all these features have been
observed by other investigators [1, 3, 4, 25, 26].
We observed that many patients on rHuEPO therapy who
had been treated at the same time with antiplatelet drugs for
preventing the thrombosis of vascular accesses for hemodialy-
sis, never developed hypertension. This observation prompted
us to analyze retrospectively the incidence of hypertension and
the possible risk factors associated with it, including the use of
antiplatelet drugs, in 91 patients on hemodialysis or continuous
ambulatory peritoneal dialysis who commenced rHuEPO ther-
apy between April 1989 and April 1992.
Methods
Patients
Eighty-five patients on maintenance hemodialysis (mean age
SD 48.5 16 years, range 18 to 78, 48 females/37 males) and
six patients on continuous ambulatory peritoneal dialysis (mean
age SD 53 19 years, range 22 to 67, 4 females/2 males) who
were receiving renal replacement therapy in three different
units dependent on our Service were included in the study. The
etiologies of renal insufficiency were: glomerulopathy (30 pa-
tients), interstitial nephritis (24 patients), diabetic (6 patients),
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vasculopathy—including malignant hypertension— (5 patients),
polycystic kidney disease (4 patients), other familiar nephrop-
athies (5 patients), and unknown origin (17 patients). Only one
patient was anephric. They were undergoing intermittent hemo-
dialysis 3 to 4.5 hours thrice weekly or 6 to 8 liter CAPD
exchanges per day, for periods which ranged from 1 to 140
months (mean SD 32 29 months). Continuous or intermit-
tent administration of sodium hepann was used as the antico-
agulant of extracorporeal circulation.
The selection criteria for entering rHuEPO therapy were
anemia with hematocrit inferior to 25% and regular need of
blood transfusions with no evidence of iron, vitamin B 12 or
folic acid deficiencies. The unique selection criterium to be
included in this study was that the course of rHuEPO therapy
must be completed, at least for an uninterrupted period of six
months from the beginning of treatment, although the cases of
treatment withdrawals due to uncontrolled hypertension before
the sixth month on therapy were included.
Through medical records, the following information for the
study was selected: history of previous hypertension and med-
ication for controlling it, baseline hematocrit before rHuEPO
therapy, mean dose of rHuEPO during the correction phase (12
first weeks on treatment) and during the first six months on
treatment, hematocrits elicited at 12 and 24 weeks on treatment,
blood pressures recorded at the beginning and at the end of each
dialysis session throughout the study period, the prescription,
type and dosage of antiplatelet drugs, as well as the changes in
antihypertensive treatment.
Erythropoietin therapy
Epoietin alfa (Eprex®, Cilag, Switzerland) was used in all but
six patients, who were treated with Epoietin beta (Erantin®,
Boehringer, Manheim, Germany). During the three year period
in which data were collected, the dose of EPO and the route
utilized was not always the same. During the first 18 months,
the dose of EPO used to correct anemia was higher than during
the latest 18 months. Similarly, during the first 18 months the
recommended route of EPO was intravenously; during the
latest 18 months the great majority of patients received EPO
subcutaneously. This fact allowed us to analyze the influence of
these two variables on the development of hypertension. All
patients received rHuEPO in a thrice-weekly regimen during
the correction phase, except the six patients on CAPD whose
regimen consisted in a once- or twice-weekly administration.
Definition of hypertension and its scores of severity
The definition of hypertension in this study was a mean blood
pressure greater than 113.3 mm Hg at the beginning of the
dialysis session, in previously normotensive patients who were
maintained for at least 15 days, which did not respond to dry
body weight decrease and which required at least one antihy-
pertensive drug to control it. In those patients with pre-existing
hypertension who were already on antihypertensive treatment,
blood pressure increase was defined with the same criteria as
that for normotensive patients, but instead of the addition of an
antihypertensive drug, the worse control of arterial blood
pressure had to require at least an increment in the dose of the
antihypertensive medication prescribed at that time. The degree
of severity of blood pressure increase was scored as follows: (1)
Mild, the increment in blood pressure was easily controlled by
one antihypertensive drug at conventional dosage in previously
normotensive patients or by increasing the dosage of the same
antihypertensive drug in patients with history of previous
hypertension; (2) Moderate, blood pressure increase was con-
trolled by adding one or two antihypertensive drugs (excluding
minoxidil) to the previous treatment in patients with or without
previous history of hypertension; (3) Severe, no successful
control of hypertension with three drugs, showing symptoms of
hypertensive encephalopathy (severe headache and visual
symptoms), which required hospital admission for controlling it
or withdrawal of rHuEPO therapy.
All 52 patients with a history of previous hypertension
maintained a good control of blood pressure before rHuEPO
treatment through controlling plasma volume (27 patients) or by
their respective antihypertensive medications (25 patients). The
antihypertensive drugs used in these patients as monotherapy
or in association were: calcium channel blockers (nifedipine,
nitrendipine or verapamil), angiotensin-converting enzyme in-
hibitors (captopril, enalapril, quinapril), and beta blockers (atenolol
and propanolol).
Use of antiplatelet drugs
The medical criteria to prescribe antiplatelet drugs and the
type of them were personally decided by the nephrologists in
charge of the hemodialysis units, according to the hypothetical
risk factors that vascular accesses for hemodialysis presented in
each case. Thus, patients with prosthetic arteriovenous fistulae
and those with internal fistulae which had previously presented
any clotting event, received more frequently antiplatelet drugs,
although none of them showed significant dysfunction of vas-
cular accesses when they were assessed by blood flow and
recirculation. Only one patient on CAPD received antiplatelet
drugs because of atherosclerotic vascular disease.
The antiplatelet drugs used in this study and the number of
patients treated with each drug were: Ditazole 400 to 800
mg/day p.o. (16 patients), Ticlopidine 250 to 500 mg/day p.o. (12
patients), and Dipirydamole 150 to 300 mg/day p.o. plus aspirin
200 mg/day p.o. (6 patients). These drugs were prescribed
before or at the same time that rHuEPO therapy was started,
and were maintained throughout the six months that comprised
the follow-up period. Since we usually do not prescribe aspirin
as an analgesic for our patients, we investigated the subrepti-
tious use of analgesics containing this drug. The analgesics most
frequently used by our patients were paracetamol and metam-
izole, none of them mixed with aspirin or non-steroidal antin-
flammatory drugs.
Statistical analysis
To analyze what factor(s) places these patients at risk to
develop hypertension, logistic regression analysis was carried
out. The dependent variable (develop hypertension or not) was
analyzed as a dichotomous entry according to the definition
displayed above. The predictors were: age, gender, number of
months on dialysis, antecedent of hypertension, baseline he-
matocrit, mean doses of rHuEPO during the correction phase
and during the first six months, route of rHuEPO administra-
tion, hematocrits elicited at 12 and 24 weeks on treatment, and
the use or not of antiplatelet drugs. Gender (male 0, female 1),
the antecedent of hypertension (normotensive 0, hypertensive
1), the route of rHuEPO administration (i.v. 0, s.c. 1) and the
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use of antiplatelet drugs (using antiplatelets 1, not using anti-
platelets 0) were analyzed as dichotomous variables. The rest of
the variables were analyzed as continuous entries. All 11
predictors were analyzed individually against the dependent
variable. From the results of the univariate regression analysis,
a multiple logistic regression model was constructed using the
maximum likelihood method.
To analyze the influence of the type of vascular access on the
development of hypertension, additional uni- and multivariate
analyses were carried out in the 85 patients on chronic hemo-
dialysis. Apart from the 11 predictor variables, the type of
vascular access was added with the following categorical trans-
formations: Cimino-Brescia fistulae I; proximal internal fistulae
2; prosthetic fistulae 3.
The logistic regression odds ratio with 95% confidence inter-
vals (CI) and P values are provided for all terms in the final
models.
Chi-square, Student's t- and Mann-Whitney tests were used
to infer proportions or means with or without normal distribu-
tions, respectively. The data are expressed in arithmetic mean
and standard deviation. A P value less than 0.05 was considered
statistically significant.
Results
Incidence of hypertension
Of the 91 patients studied, 34(37%) developed hypertension.
Seven patients showed mild hypertension, 16 moderate and 11
severe. Headache was the most common symptom complained
by those patients who developed severe hypertension, but none
of them suffered convulsions. rHuEPO had to be discontinued
in three patients due to severe uncontrolled hypertension. The
time elapsed between commencement of rHuEPO and blood
pressure increase ranged between 3 and 18 weeks (mean SD
8.7 4 weeks).
All 34 patients considered as developing hypertension had a
sustained increment in blood pressure well above 15 mm Hg
before antihypertensive medication was introduced or aug-
mented. However, three patients, who were not considered as
developing hypertension because mean blood pressure did not
reach 113.3 mm Hg, showed an increment in blood pressure
greater than 15 mm Hg. These three patients were not taking
antiplatelet drugs.
Clinical characteristics between patients who developed or
not hypertension
The main characteristics of patients who developed or did not
develop hypertension are summarized in Table 1. Patients who
developed hypertension were younger, presented more fre-
quently the antecedent of hypertension and only two of them
received antiplatelet drugs, whereas 32 out of 57 patients who
did not develop hypertension, were taking this medication.
Patients who developed hypertension received a slightly greater
mean dose of rHuEPO during the correction phase as well as
during the first six months, but the difference did not reach
statistical significance. There were no other statistically signif-
icant differences in the rest of the variables compared between
both groups.
The main clinical differences between the 25 patients who did
not develop hypertension while they were not treated with
Patients
Age years
Gender
Time on dialysis
months
Antecedent of
hypertension
On antiplatelet
therapy
Baseline hematocrit
Hematocrit at 12
weeks
Hematocrit at 24
weeks
Mean dose rHuEPO
correction phase
U/kg/weekly
Mean dose rHuEPO
during the 6
months
U/kg/weekly
Route of rHuEPO
administration
a P = 0.001 (unpaired t-test)b P < 0.02 (Chi-square)
P < 0.0001 (Chi-square)P = 0.09 (unpaired t-test)
20.8 1.8%
29.5 4.1%
20.7 1.7%
28.8 3.4%
31.3 2% 31.7 2.7%
126 57d 108 49
117±57 106±46
20 s.c./14 i.v. 34 s.c./23 iv.
antiplatelet drugs and the 32 untreated patients who developed
hypertension, were: age (52 15 vs. 40.5 17 year, P = 0.014,
unpaired t-test), and the prevalence of previous hypertension
(28% vs. 71%, P = 0.001, Chi-square). The rest of the clinical
characteristics did not show statistically significant differences.
Confounding factors: Clinical characteristics between
patients who received antiplatelet drugs or not
The characteristics of patients who were or not on antiplate-
let therapy are summarized in Table 2. Patients on antiplatelet
drugs were older and a larger proportion of them were females.
These differences are easily explained by the greater difficulty
to accomplish a vascular access in patients with these charac-
teristics, and the need to protect it against thrombosis. Seven
patients on antiplatelet therapy had prosthetic fistulae, 11
proximal internal fistulae, and the other 15, Cimino-Brescia
fistulae. Only three of the patients who were not taking anti-
platelet drugs had prosthetic fistulae; 11 had internal proximal
fistulae and 38 Cimino-Brescia fistulae. Patients on antiplatelet
therapy had a higher prevalence of previous hypertension, but
only two of them developed blood pressure increase following
rHuEPO. One of these patients showed a mild hypertension,
and the other showed moderate hypertension. The incidence of
hypertension was 56% among those patients who were not
taking antiplatelet drugs. The rest of the characteristics com-
pared between these two groups did not show statistically
significant differences.
Of the 57 patients not treated with antiplatelet drugs, seven
developed fistula clotting, while only one out of 34 patients who
were taking antiplatelet drugs developed fistula thrombosis (P
= 0.254, Chi-square with continuity correction). Five out of
Table 1. Characteristics of patients who developed or not
hypertension following rHuEPO treatment
Developed
hypertension
34 (37%)
40.5 17
18 males/16 females
33 32
25 (73%)"
2(5%)
Not developed
hypertension
57(63%)
53.8 16
2 I males/36 females
32 27
27 (47%)
32 (56%)C
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With antiplatelet Without antiplatelet
Patients 34 57
Age years 54 17 45 17
Gender 12 males/22 females 27 males/30 females
Time on dialysis 27 27 36 30"
months
Antecedent of 22 (65%) 30 (53%)
hypertension
Baseline hematocrit 21,1 1.8% 20.5 1.8%
Hematocrit at 12 29.4 4% 28.8 4%
weeks
Hematocrit at 24 32 2.3% 31.3 2.5%
weeks
Mean dose rHuEPO 106 42 119 57
correction phase
U/kg/weekly
Mean dose rHuEPO 102 41 114 55
during the 6
months
U/kg/weekly
Route of rHuEPO 24 s.c./10 i.v. 31 s.c./26 i.v.
administration
hypertension.
Antiplatelet therapy did not cause major adverse effects.
Four patients showed minor bleeding disorders (echimosis or
epistaxis), but none of them required treatment withdrawal.
Uni- and multivariate logistic regression analyses
By univariate logistic regression, three variables showed
statistically significant associations with the development of
hypertension (Table 3). The age of the patients (odds ratio
0.953, 95% C.!. 0.927 to 0.979, P = 0.0007), the antecedent of
hypertension (odds ratio 3.086, 95% C.!. 1.227 to 7.763, P =
0.016), and the use of antiplatelet drugs (odds ratio 0.048, 95%
C.!. 0.0106 to 0.223, P = 0.0001) correlated with the develop-
ment of hypertension. The dose of rHuEPO during the correc-
tion phase showed a weaker statistical correlation with hyper-
tension (odds ratio 1.006, 95% C.!. 0.998 to 1.015, P = 0.106).
The rest of the studied variables failed to show statistically
significant correlations with the dependent variable.
By multiple logistic regression (Table 4), the variables which
better contributed to explain the development of hypertension
in our patients were: age, antecedent of hypertension, and use
of antiplatelet aggregant drugs. As in Table 4, when the ante-
cedent of hypertension and the use of antiplatelet drugs were
added to the model, the importance of age became markedly
less.
By univariate regression analysis restricted to the 85 patients
on chronic hemodialysis, the type of vascular access correlated
inversely with the development of hypertension (odds ratio
0.452, 95% C.I. 0.206 to 0.993, P =0.048), but when the age and
the previous history of hypertension and antiplatelet therapy
were added to the multivariate model, the importance of the
type of vascular access became null (95% C.!. odds ratio 0.3 32
to 2.826, P 0.932).
Discussion
The results of this study show that hypertension developed in
about 37% of the patients during the first six months on
rHuEPO therapy, and by multiple logistic regression analysis,
two factors were identified that negatively affected the inci-
dence of hypertension (the previous history of hypertension and
younger age), but antiplatelet therapy dramatically diminished
the probability to develop this adverse effect. The incidence of
hypertension induced by rHuEPO in this study is similar to
what has been reported in other large series based on mainte-
nance hemodialysis patients [1—5], although in smaller series,
the reported incidences of hypertension have been notoriously
divergent [11, 13, 19, 27—31]. These differences are likely
influenced by the definition of hypertension taken in each study.
If we had only considered the values of blood pressure,
disregarding the amount of antihypertensive medications, our
own incidence would have been smaller because it would have
considered only the cases of severe hypertension. Notwith-
standing, the incidence of this adverse effect may also depend
on patient selection and the presence or absence of determined
risk factors not yet recognized.
The history of previous hypertension as a risk factor for
developing blood pressure increase following rHuEPO is con-
troversial. While some investigators have not observed a
greater incidence of hypertension among their previously hy-
pertensive patients compared to the normotensive ones [1, 4,
191, others have considered it as an important risk factor [2, 3,
29, 31]. In this study, the incidence of hypertension among
patients with a history of previous hypertension was 48%,
whereas among normotensive patients it was 23%. These fig-
ures are very similar to what has been reported among previ-
ously hypertensive patients [2] as well as among previously
normotensive patients [30]. Furthermore, the antecedent of
hypertension contributed as a predictive variable in the best
model of multiple logistic regression constructed in this study.
Along with the history of previous hypertension, age was
considered the other variable that negatively affected the inci-
dence of hypertension. Younger patients showed a higher risk
for developing hypertension than the more elderly ones. This
finding could be influenced by the fact that elder patients more
frequently received antiplatelet drugs. Indeed, when we ana-
lyzed by univariate logistic regression the correlation between
age and the development of hypertension, the regression coef-
ficient was sensibly lower than when we introduced in the
multiple regression model the use of antiplatelet therapy and the
antecedent of hypertension, although age remained a predictive
variable.
The baseline hematocrit and the hematocrits elicited at 12 and
24 weeks on treatment or the route of rHuEPO administration
failed to explain the development of hypertension in this study.
The mean dose of rHuEPO during the correction phase only
showed a weak correlation with the development of hyperten-
sion when it was determined by univariate analysis, but it no
longer remained statistically significant in multiple regression
models.
The results of this study point toward antiplatelet therapy as
an independent factor which may prevent the development of
hypertension induced by this hormone. Dipirydamole has an
intrinsic vasodilatory effect 1321, but we think this effect is so
Table 2. Characteristics of patients with or without antiplatelet
treatment
P = 0.018 (unpaired t test)b P = 0.06 (Mann-Whitney test)
seven untreated patients with fistula thrombosis developed
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Table 3. Univariate regression analysis over the development of hypertension
Regression
Predictive variable coeff. SE Odds ratio C,I. 95% odds ratio P
Age —0.0475 0.0139 0.953 0.927—0.979
Antecedent hypertension 1.1270 0.4706 3.086 1.227—7.763
Antiplatelet therapy —3.0194 0.7762 0.048 0.010—0.223
Dose EPO in the correction phase 0.0068 0.0042 1.006 0.998—1.015
0.0007
0.0166
0.0001
0. 1061
Table 4. The best multiple logistic regression model to explain the development of hypertension induced by rHuEPO
Regression
Predictive variables coeff. 5E Odds ratio IC 95% odds ratio P
Age —0.0411 0.0177 0.9597 0.993—0.927
Antecedent hypertension 1.8 169 0.6070 6. 1528 20.218—1.872
Antiplatelet therapy —3.503 1 0.8674 0.0301 0.0055—0.1648
Intercept 1.260 0.9334
0.02
0.0028
<0.0001
Likelihood ratio: 45.29; P < 0.0001.
slight that it cannot explain the preventive action on the
development of hypertension. Ticlopidine has not been shown
to have a significant hemodynamic effect in clinical trials [331,
but in rats with ablation of renal mass the addition of this drug
has been shown to afford a beneficial effect on blood pressure
control through a mechanism not yet elucidated [34]. As far as
we know, Ditazole has no vasodilatory effect [35]and it was as
effective as dipirydamole and ticlopidine in preventing hyper-
tension. The search for confounding factors, which might have
alternatively explained the low incidence of hypertension in the
group of patients treated with antiplatelet drugs, was negative
except that patients who received this therapy had proportion-
ally more prosthetic and proximal vascular accesses than pa-
tients who were not receiving antiplatelet agents. It has been
reported that arteriovenous fistulae may be an important source
of endothelin- 1 production [36], however, the investigators of
this work do not offer enough information about the types of
arteriovenous flstulae studied. Furthermore, according to the
hypothesis proposed by some investigators [9] that rHuEPO-
induced hypertension may be caused by an innapropriate
reduction of cardiac output following correction of anemia, and
taken into consideration that proximal venous fistulae can
provoke a hyperdynamic state, a higher incidence of hyperten-
sion would have been expected among patients with these types
of fistulae. By univariate regression analysis restricted to the 85
patients on chronic hemodialysis, proximal internal and pros-
thetic fistulae correlated negatively with the development of
hypertension. When the age, the previous history of hyperten-
sion and antiplatelet therapy were added to a multivariate
model, the importance of the type of vascular access as
predictor over the development of hypertension became null.
Thus, surrounding conditions associated to determined types of
fistulae, as the age and the prescription of antiplatelet drugs,
seem to be more important than the fistula itself in the devel-
opment of hypertension induced by EPO.
The effect of rHuEPO on the hemopoiesis is not restricted to
the erythroid lineage. In vitro studies have demonstrated that
rHuEPO can stimulate the production and maturation of mega-
karyocytes [37—40]. Platelet aggregability is enhanced following
rHuEPO treatment [41—43], but this effect cannot be demon-
strated when hematocrit rises with blood transfusions [42].
Moreover, an increment in circulating thrombin-antithrombin
III complex in patients treated with rHuEPO has been reported
[44], suggesting the existence of an active thrombotic process
during the first weeks on treatment, although it is likely that this
thrombotic process may be located only in the extracorporeal
circulation of patients undergoing hemodialysis [45] orpossibly
stimulated by this procedure. All these changes in platelet
function as well as the indirect evidence of a procoagulant effect
induced by rHuEPO are transient [41, 42, 44] and reach their
maximun expression simultaneously with the peak of maximun
incidence of blood pressure increase in these patients. Some
investigators have postulated that the same mechanism by
which rHuEPO would be able to enhance platelet aggregability
may also provoke blood pressure increase [29]. An increment in
intracellular free calcium mobilization in platelets and possibly
in smooth muscle cells has been the hypothesis proposed by
these investigators [29]. Schiffi [30] observed a close correlation
between free calcium concentration in platelets and mean
arterial pressure in eight previously normotensive patients who
had developed hypertension following rHuEPO therapy, but
other investigators [8] have been unable to demonstrate this
correlation among their patients.
In view of the results presented here, a causal-effect relation-
ship between changes in platelet aggregability and the incre-
ment in blood pressure induced by rHuEPO is hypothesized.
The beneficial effect of antiplatelet drugs on preventing hyper-
tension may be related with recent evidence that rHuEPO could
induce changes in the secretory capacity of endothelium [46,
47]. According to these investigators, a shift in the balance
between constrictor and relaxing prostanoids [46] along with an
increment in the production and release of endothelin-l [46, 47]
would lead to vascular hyperreactivity. However, further stud-
ies will be required in order to more exactly ascertain the role of
vasoactives prostanoids in the regulation of blood pressure in
uremic patients, the effect of rHuEPO on these vasoactive
substances, and the hypothetical effect of platelet activation on
potentiating endothelial dysfunction.
In conclusion, antiplatelet therapy may prevent the develop-
ment of hypertension induced by rHuEPO therapy. Definitive
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conclusions should be derived from prospective studies, which
are currently underway.
Reprint requests to F. Caravaca, M.D., S. NefrologIa, Hospital
Infanta Cristina, 06080 Badajoz, Spain.
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